ClinicalTrials.gg
RecruitingNCT07212829Updated Apr 20, 2026

The Added Value of Transcranial Direct Current Stimulation (tDCS) During Exercise for People With Chronic Widespread Pain

An interventional study of Active tDCS and Aerobic exercise in Chronic Widespread Pain and Fibromyalgia (FM), sponsored by Vrije Universiteit Brussel. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Vrije Universiteit Brussel · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Chronic Pain by Vrije Universiteit Brussel — 4 open to participants now, 4 under way, none of them phase 3. Chronic Pain · Vrije Universiteit Brussel.

Planned enrollment
2nd of 10
120 · median 57
Started
2026
the only one that year
No phase
8 of 16
2 open now
Registered
16th of 16
by date

Among the 16 studies in Chronic Pain by Vrije Universiteit Brussel, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 16th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

4 of the 16 studies in Chronic Pain by Vrije Universiteit Brussel are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Chronic Pain by Vrije Universiteit Brussel, or all of them as a file.
02

Study summary

Many people with chronic widespread pain (CWP) feel more pain and fatigue after exercise. This makes it hard to stay active. Unfortunately, the investigators do not fully understand why this happens and how to prevent it.

The primary goal of this study is to explore the underlying genetic and epigenetic mechanisms of BDNF gene in response to exercise, and investigate if transcranial direct current stimulation (tDCS) during exercise works to improve worsening symptoms response to exercise in people with CWP.

The investigators designed a randomized crossover study and will enroll 60 patients with CWP and 60 healthy controls. Participants will undergo 2 interventions in random order: 1) exercise + active tDCS, and 2) exercise + sham tDCS. Participants will visit the hospital twice with at least one week in between the visits.

Read the detailed description

Many people with chronic widespread pain (CWP), such as those with fibromyalgia, experience increased pain in response to exercise, which discourages continued physical activity. Although abnormal gene expression via epigenetic mechanisms has been implicated in CWP, the underlying mechanisms by which exercise exacerbates symptoms remain unclear. DNA methylation is one way that environmental factors like exercise can alter gene expression, and brain-derived neurotrophic factor (BDNF) plays a central role in both neuroplasticity and pain processing. The investigators hypothesize that aberrant expression of the BDNF gene contributes to post-exercise symptom flares in CWP.

Transcranial direct current stimulation (tDCS) has been shown to modulate neuroplasticity and influence gene expression, making it a promising approach to normalize BDNF regulation during exercise.

In this randomized crossover trial, 60 CWP patients and 60 healthy controls will each undergo two sessions: (1) exercise with active tDCS and (2) exercise with sham tDCS. Each participant will visit the hospital twice, with at least one week between sessions. During each session, participants will receive one bout of submaximal aerobic exercise (20 min), along with a single session of active or sham tDCS (30 min) simultaneously. The order of interventions will be well-balanced and randomly allocated to each participant. We will measure pain intensity, serum BDNF protein levels, and BDNF gene methylation before and after each session. To capture longer-term effects, participants will also complete online symptom assessments at 8 hours, 24 hours, 48 hours, and 7 days post-exercise.

The primary objective of this study is to determine how active versus sham tDCS during exercise influences BDNF expression, DNA methylation patterns, and pain intensity in CWP patients.

The secondary objectives are to 1) compare these tDCS-induced changes between CWP patients and healthy controls; and 2) identify factors that influence tDCS/exercise-induced changes, including baseline BDNF levels, DNA methylation patterns, genetic polymorphisms and Lifestyle variables (e.g., physical activity).

By elucidating the epigenetic regulation of BDNF in exercise-induced pain and evaluating tDCS as a modulatory intervention, this study seeks to identify biomarkers of symptom exacerbation and develop non-pharmacological strategies that enable CWP patients to remain active without worsening their pain.

03

Conditions studied

  • Chronic Widespread Pain
  • Fibromyalgia (FM)

Keywords

  • BDNF
  • pain
  • exercise
  • DNA methylation
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients

Participants in the patient group must meet all of the following criteria:

  1. Diagnosis of chronic widespread pain (CWP) or fibromyalgia;
  2. Age between 18 and 70 years old;
  3. (BMI) ≤ 35;
  4. Widespread Pain Index (WPI) assessment: the WPI questionnaire (0-19 points) will be used to record the number and distribution of painful body sites. Participants will be classified as having CWP if pain is reported on both sides of the body, above and below the waist, and in the axial skeleton, with pain symptoms lasting ≥ 3 months;
  5. Stable medication use for at least 1 month prior to study entry.

Healthy control group

Participants in the healthy control group must meet all of the following criteria:

  1. Age between 18 and 70 years old;
  2. Body mass index (BMI) ≤ 35;
  3. No chronic conditions, such as chronic pain and diabetes.

Exclusion criteria

Exclusion Criteria:

For both patients and healthy controls, participants will be excluded if they meet any of the following:

  1. Current pregnancy or pregnancy within the past 12 months;
  2. for non-invasive brain stimulation (NIBS), in line with published safety guidelines;
  3. History of neurological disorders, including epilepsy (personal or family history), traumatic brain injury, stroke, dementia, or Parkinson's disease;
  4. Major medical conditions, including cancer, endocrine or metabolic disorders, urine, genital and cardiovascu-lar diseases (e.g., myocardial infarction, heart failure, arrhythmia, uncontrolled hypertension).
  5. Substance abuse.
  6. Presence of psychiatric disorders other than depression or anxiety.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Exercise + active tDCS + patients

    Patient participants will receive one bout of submaximal aerobic exercise, along with a single session of active tDCS simultaneously.

    Device: Active tDCS · Behavioral: Aerobic exercise

  • Sham comparator
    Exercise + sham tDCS + patients

    Patient participants will receive one bout of submaximal aerobic exercise, along with a single session of sham tDCS simultaneously.

    Behavioral: Aerobic exercise · Device: Sham tDCS

  • Active comparator
    Exercise + active tDCS + healthy controls

    healthy volunteer participants will receive one bout of submaximal aerobic exercise, along with a single session of active tDCS simultaneously.

    Device: Active tDCS · Behavioral: Aerobic exercise

  • Sham comparator
    Exercise + sham tDCS + healthy controls

    healthy volunteer participants will receive one bout of submaximal aerobic exercise, along with a single session of sham tDCS simultaneously.

    Behavioral: Aerobic exercise · Device: Sham tDCS

Interventions

  • DeviceActive tDCS

    tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site). For active tDCS, the current is ramped up for 30 seconds until the center electrode reaches a target intensity of 2 mA, then remains for 29 minutes before dropping for another 30s.

  • BehavioralAerobic exercise

    Participants will perform a moderate aerobic exercise (AE, known as aerobic power index), using a cycle er-gometer. The exercise intensity is moderate and individually tailored based on each participant's estimated maximum heart rate (HRmax), calculated using the validated formula: HRmax = 211 - (0.64 × age).

  • DeviceSham tDCS

    tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site). In the sham condition, current is ramped up to 2.0 mA for 30 seconds and then ramped down to 0 mA, with the total session duration matched to the active condition. This procedure was used to mimic the tingling sensa-tions typically experienced at the beginning of stimulation. Participants received identical instructions, session timing, and room setup across conditions.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Pain intensity is measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no pain" and 10 indicates "the worst pain imaginable".

    Time frame: Participants rate their pain at baseline, and 30 minutes after the intervention.

  2. Blood BDNF levels

    Venous blood samples are collected before and after each exercise-tDCS session. Samples are centrifuged, aliquoted, and stored at -80 °C until analysis. Blood levels of brain-derived neurotrophic factor (BDNF) are quantified using a commercially available enzyme-linked immunosorbent assay (ELISA), following the manufacturer's instructions.

    Time frame: Blood samples are collected at baseline and 20 minutes after exercise-tDCS session.

  3. BDNF DNA methylation

    Genomic DNA is extracted from whole blood collected at baseline and after the intervention. DNA methylation of the BDNF gene is assessed using bisulfite conversion followed by quantitative analysis of methylation levels at CpG sites within promoter regions previously associated with pain regulation. Methylation levels are expressed as the percentage of methylated cytosines at each CpG site. Changes in DNA methylation are calculated as the difference between post-intervention and baseline values.

    Time frame: Blood samples are collected at baseline and 20 minutes after exercise-tDCS session.

Secondary outcomes

  1. Pain intensity

    Pain intensity is measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no pain" and 10 indicates "the worst pain imaginable".

    Time frame: Participants rate their pain at immediately, 8 hours, 24 hours, 48 hours, and 7 days after the intervention.

  2. Fatigue

    Brugmann Fatigue Scale (BFS). Fatigue is assessed with the BFS, an 8-item self-report questionnaire (4 mental and 4 physical items; each scored 0-3). Subscale scores range 0-12 (mental; physical), and the total score ranges 0-24; higher scores indicate greater fatigue/rest propensity.

    Time frame: Participants rate their fatigue at baseline, and 24 hours, 48 hours, 7 days after the intervention.

  3. Fibromyalgia symptom impact

    Revised Fibromyalgia Impact Questionnaire (FIQR). The FIQR evaluates the overall impact of fibromyalgia on functioning, symptoms, and quality of life. The total score ranges 0-100 (higher = greater disease burden), comprising function (0-30), overall impact (0-20), and symptoms (0-50) after standard weighting; each item is rated 0-10.

    Time frame: Participants rate their FIQR at baseline, and 7 days after intervention.

  4. Central sensitization symptoms

    The Central Sensitization Inventory (CSI) is administered to assess symptoms related to central sensitization, such as sensitivity to touch, light, or sound, sleep disturbances, and concentration difficulties. Scores range from 0 to 100, with higher scores reflecting greater symptom severity. Each item is rated 0-4.

    Time frame: Participants rate their CSI at baseline.

  5. Pain catastrophizing

    The Pain Catastrophizing Scale (PCS) is used to measure catastrophic thoughts and feelings related to pain, in-cluding rumination, magnification, and helplessness. Each item is rated 0-4. Total scores range from 0 to 52, with higher values indicating stronger pain catastrophizing tendencies.

    Time frame: Participants rate their PCS at baseline, and 30 minutes after the intervention.

  6. Anxiety and depression

    HADS consists of two subscales: HADS-A, designed to detect anxious states, and HADS-D, designed to detect de-pressive states. Each subscale consists of 7 items with a 4-point ordinal response format. Scores range from 0 to 21 in each subscale, with higher scores indicating higher levels of anxious or depressive state. Participants an-swer each item thinking of how they felt and/or behaved during the past week.

    Time frame: Participants rate their HAD at baseline.

07

Study locations

1 of 1 sites recruiting
  • VUB
    Jette, 1090, Belgium
    Recruiting
    • Pain in Motion research group, PhD · ContactJo.Nijs@vub.be · +32 0497783956
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 22 months is close to that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 8, 2025
StartActual
Feb 1, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07212829
Responsible party
Jo Nijs (Principal Investigator, Vrije Universiteit Brussel) — Principal investigator
First posted
Oct 8, 2025
Start date
Feb 1, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 20, 2026

Study contacts

Pain in Motion research group
Contact
huanyu.xiong@vub.be
+32 497783956

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion